- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Plan sponsors seek clear path to lowest net drug costs
Transparent models are fee-based, but do plan sponsors gain anything from such arrangements?
"Every PBM offers a transparency proposal, but when one drills in closer, it really isn't," Thomas says. "Many PBMs have artificially created a transparency model that looks inferior to traditional models, leaving payers with the belief that traditional model pricing is a superior offer."
DRIVING MORE TRANSPARENCY
One of the more outspoken organizations challenging PBM operations is the National Community Pharmacists Assn. (NCPA), which has a litany of complaints regarding: disclosure of rebates and fees to plan sponsors; pharmacist reimbursement for generic fills; price inflation of drugs dispensed through mail; incentives to encourage the use of more expensive brand drugs over generics; and lack of pass-through on savings from manufacturer discounts.
"Plans need to know, because what they don't know will hurt them," says John Coster, senior vice president, government affairs for NCPA. "They need to be educated about the ways PBMs may be increasing drug costs and if PBMs are improving outcomes. We believe that rebates are at the heart of the PBM business model and ought to be eliminated. As manufacturer rebates increase, drug companies drive up costs to compensate, as well as increase the use of brands which generate rebates. Call a rebate a rebate without any skimming off the top."
Although the lack of transparency is drawing attention, not every plan sponsor is demanding the fee-based, transparent model, according to Medco Health Solutions, a PBM based in Franklin Lakes, N.J.
"Transparency is not as an important an issue today as it was six years ago," says Tim Wentworth, Medco's group president of employer accounts. "There has been a fundamental change in the alignment between PBMs and their clients with disclosure on how a PBM makes its money and through an increase in the use of generics. There was a concern about rebate dollars and whether they were flowing 100% in the client's direction."
He says some of the company's clients prefer the traditional model. Medco is one of the three biggest PBMs, which are receiving most of the criticism.
But PBMs are more than just fillers of prescriptions. Wentworth says the company offers value by playing an integral role in healthcare by identifying high-cost members, while offering preventive, clinical drug utilization and therapeutic benefit guarantees.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Upended: Can PBM Transparency Succeed?
March 6th 2024Simmering tensions in the pharmacy benefit management (PBM) industry have turned into fault lines. The PBMs challenging the "big three" have formed a trade association. Purchaser coalitions want change. The head of the industry's trade group says inherent marketplace friction has spilled over into political friction.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
In this second part of a video series, AMCP CEO Susan Cantrell addressed the impact of high prescription drug prices on underserved communities, highlighting disparities in access caused by the pandemic's effects on minority populations. On the industry blame debate, she urged collaborative solutions, mentioning AMCP's engagement with diverse stakeholders to find comprehensive, patient-centric solutions and advocate for policy changes like the MVP Act to address rising costs and access challenges.
Read More
